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Dallas, TX; London, United Kingdom; Brisbane, CA; Chennai, India; and Ontario, CanadaExenatide once-weekly is an extended release formulation of exenatide, a glucagon-like peptide–1 receptor agonist, which can
improve glycemic control, body weight, blood pressure, and lipid levels in patients with type 2 diabetes mellitus (T2DM). The
EXenatide Study of Cardiovascular Event Lowering (EXSCEL) will compare the impact of adding exenatide once-weekly to usual
care with usual care alone on major cardiovascular outcomes.
EXSCEL is an academically led, phase III/IV, double-blind, pragmatic placebo-controlled, global trial conducted in 35
countries aiming to enrol 14,000 patients with T2DM and a broad range of cardiovascular risk over approximately 5 years.
Participants will be randomized (1:1) to receive exenatide once-weekly 2 mg or matching placebo by subcutaneous injections.
The trial will continue until 1,360 confirmed primary composite cardiovascular end points, defined as cardiovascular death,
nonfatal myocardial infarction, or nonfatal stroke, have occurred.
The primary efficacy hypothesis is that exenatide once-weekly is superior to usual care with respect to the primary composite
cardiovascular end point. EXSCEL is powered to detect a 15% relative risk reduction in the exenatide once-weekly group, with 85%
power and a 2-sided 5%alpha. The primary safety hypothesis is that exenatide once-weekly is noninferior to usual carewith respect
to the primary cardiovascular composite end point. Noninferiority will be concluded if the upper limit of the CI is b1.30.
EXSCEL will assess whether exenatide once-weekly can reduce cardiovascular events in patients with T2DM with a broad
range of cardiovascular risk. It will also provide long-term safety information on exenatide once-weekly in people with T2DM.
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http://dx.doi.org/10.1016/j.ahj.2015.12.009the majority of whom will die from cardiovascular
disease.2,3 Epidemiological analyses of United Kingdom
Prospective Diabetes Study data from newly diagnosed
T2DM identified higher low-density lipoprotein choles-
terol, lower high-density lipoprotein cholesterol, hyper-
glycemia, hypertension, and smoking as potentially
modifiable cardiovascular risk factors.4 However, even
after adjustment for these factors, people with T2DM
remain at double the cardiovascular risk as those without
T2DM.5 Although the prevalence of cardiovascular
disease has declined progressively in the general popu-
lation, the higher relative risk for cardiovascular disease
in people with T2DM has not changed over the last 50
years.6 It would therefore be advantageous if new
glucose-lowering medications could reduce cardiovascu-
lar risk, in addition to improving glycemic control.
Exenatide (Byetta, AstraZeneca, Wilmington, DE) is the
first in class glucagon-like peptide (GLP)–1 receptor
agonist. It reduces glucose levels in people with T2DM by
a number of mechanisms, including enhancing insulin




minimizing the risk of hypoglycemia in the absence of an 
insulin secretagogue or exogenous insulin. Exenatide has 
also been shown to have beneficial effects on blood 
pressure and blood lipids and to facilitate weight loss.7-11 
Mechanistic data suggest that exenatide can improve 
cardiac function in patients with chronic heart failure,12 
improve endothelial dysfunction,13 and reduce infarct 
size after ST-segment elevation myocardial infarction.12,14 
A patient-level integrated meta-analysis showed no 
evidence for increased cardiovascular disease risk with 
use of exenatide in subjects with T2DM,15 whereas a 
retrospective analysis of a medical and pharmaceutical 
insurance claims database found a lower relative cardio-
vascular disease risk associated with exenatide treatment 
than with other glucose-lowering drugs.16 A small
increase in heart rate has been observed with GLP-1 
receptor agonists, which appears to be a class effect.17
The EXenatide Study of Cardiovascular Event Lowering 
(EXSCEL) will evaluate the effect of a once-weekly 
formulation of exenatide (Bydureon)18 on major cardio-
vascular events when given in addition to usual care.
Study design
Overview
EXSCEL is a multinational, placebo-controlled, double-
blind, parallel-group pragmatic trial randomizing patients 
with T2DM to receive once-weekly exenatide or match-
ing placebo (unloaded microspheres), in addition to their 
usual care (Figure). It will assess the impact of
once-weekly exenatide therapy in approximately 14,000 
patients, with or without known cardiovascular disease, 
from heterogeneous practice environments in 35 coun-
tries from North and South America, Europe, Africa, Asia, 
and Australasia. EXSCEL is planned to continue until 
1,360 patients with a confirmed primary composite 
cardiovascular end point (defined as cardiovascular 
death, nonfatal myocardial infarction, or nonfatal stroke) 
have been accrued or until the independent Data Safety 
Monitoring Board (DSMB) recommends otherwise. All 
patients who prematurely discontinue study treatment 
should continue subsequent study visits and posttreat-
ment follow-up evaluations.
The sponsor of the trial, AstraZeneca, participated in 
the design of the trial and protocol in collaboration with 
the academic members of the executive committee. The 
sponsor was responsible for submission of the protocol 
for approval by national regulatory authorities. The 
sponsor had no role in data collection, in data analysis, 
or in the decision to submit the manuscript for 
publication. The authors are solely responsible for the 
drafting and editing of the article and its final contents.
Trial population
Adults with T2DM, with or without additional
cardiovascular risk factors or prior cardiovascular events,are eligible if their usual care hemoglobin A1c (HbA1c) is
48 mmol/mol to 86 mmol/mol (6.5% to 10.0%) inclusive.
Study participants can be treated with up to 3 oral
glucose-lowering drugs of any type or insulin (alone or in
combination with up to 2 oral glucose-lowering drugs).
Detailed inclusion and exclusion criteria and the rationale
for their selection are outlined in Supplementary
Appendix A. During the trial, patients will still be
managed by their usual care provider and treated
according to local standards of care for diabetes and
cardiovascular risk factor management. They will attend
study clinics only for provision of study medication and
follow-up. In some cases, the site investigator may also be
the usual care provider.
Study drug
Patients will be allocated centrally at random in a 1:1
ratio to receive once-weekly subcutaneous injections of
exenatide (Bydureon) 2 mg or matching placebo
stratified by whether or not they have a history of
cardiovascular disease. Once-weekly exenatide was
approved for the treatment of patients with T2DM by
the European Medicines Agency in 2011 and the United
States Food and Drug Administration (FDA) in 2012. It
acts by augmenting insulin secretion and reducing
glucagon secretion in a glucose-dependent manner.19
Once-weekly exenatide was developed by encapsulating
exenatide in microspheres of a biodegradable polymer,
resulting in sustained drug delivery over a period of
weeks after subcutaneous injection.18
Concurrent glycemic therapy
It is expected that patients will see their usual care
provider at least twice per year for routine care. Although
there is no requirement to achieve glycemic equipoise
between the 2 randomized groups, it is anticipated that
there will be little or no between-group difference in
achieved glucose levels during the double-blind treat-
ment period, as diabetes therapy will be adjusted by the
usual care providers according to local guidelines. This
can involve the addition or substitution of any glucose-
lowering therapies, including insulin, but excluding
GLP-1 receptor agonists. Concomitant medication chang-
es are permitted at any time, but unless there are safety
concerns, usual care providers will be asked to avoid
them immediately after randomization while HbA1c
levels are reflecting the initial effect of study medication.
Treatment protocol and follow-up
EXSCEL is a pragmatic trial20 designed to investigate the
effectiveness of once-weekly exenatide with a view to
providing generalizable results. The entry criteria are
consistent with the range of patients who might receive
once-weekly exenatide in routine clinical practice,
including those at high and moderate cardiovascular risk.
Figure
Design of the EXSCEL trial: It is planned to continue until 1,360 patients with a confirmed primary composite cardiovascular end point have been
accrued.To minimize interference with usual care, the number
of monitoring visits will be limited. Patients will be
trained at randomization to self-administer once-weekly
exenatide and seen at 1 week to have their self-injection
observed. Subsequently, patients will be seen at 2
months, 6 months, and every 6 months thereafter until
study close out (Figure).
At all visits postrandomization, there will be an
assessment of clinical events and serious adverse events,
as well as a review of concomitant medication and
adherence to study medication. At annual visits, addi-
tional procedures will include ascertainment of blood
pressure, body weight, and heart rate; and the most
recent HbA1c, lipid profile, and serum creatinine data
will be ascertained opportunistically from local laborato-
ry usual care records. Patients will also be asked to
complete a standardized self-reported health status
questionnaire (European Quality of Life-5 Dimensions).21
The first patient was randomized on 18 June 2010, and
follow-up will continue until a total of 1,360 patients with
an adjudicated and confirmed primary composite cardio-
vascular outcome have been accrued.
Primary outcomes
The EXSCEL primary efficacy hypothesis is that
once-weekly exenatide is superior to usual care with
respect to the adjudicated primary composite cardiovas-
cular end point. The primary safety hypothesis is that
once-weekly exenatide is noninferior to usual care with
respect to the adjudicated primary cardiovascular com-
posite end point.
Secondary outcomes
Adjudicated secondary end points are all-cause mortal-
ity, the individual components of the primary composite
cardiovascular outcome (cardiovascular death, nonfatalmyocardial infarction, and nonfatal stroke), hospitaliza-
tion for acute coronary syndrome, and hospitalization for
heart failure (Supplementary Appendix B lists all second-
ary and exploratory efficacy end points).
Participant safety
Adverse events will be monitored over the course of
the trial, starting from the time of randomization and
through the duration of the patient’s participation,
including the 70-day posttrial medication follow-up
period. In this pragmatic trial, only adverse events that
are serious or lead to discontinuation of study medication
will be recorded. EXSCEL will use both patient- and
investigator-directed education to minimize the risk of
hypoglycemia. Symptoms and appropriate management
of hypoglycemia will be reviewed at all study visits. Usual
care providers will be responsible for the adjustment of
concomitant therapy. Two or more severe episodes
(hypoglycemia requiring assistance) between visits,
despite appropriate titration of glucose-lowering thera-
pies, will trigger permanent discontinuation of study
medication.
Patients with an estimated glomerular filtration rate
(eGFR) b30 mL/(min 1.73 m2) (calculated using Modifi-
cation of Diet in Renal Disease–4)22 will be excluded
because exenatide is renally excreted.23 During the trial,
patients with 2 successive values less than this eGFR
threshold will be discontinued from study medication. If
a usual care annual creatinine value is not available, it will
be measured by the site to support patient safety.
In view of concerns raised in animal studies about a
possible increase in thyroid C-cell adenomas and carci-
nomas,24,25 the FDA has requested that calcitonin be
assayed by a central laboratory at screening and annually
thereafter. These will be scrutinized centrally. If the
screening value is N40 ng/L or a subsequent annual value
is ≥50 ng/L, study medication will be permanently 
discontinued and the patient referred for clinical 
evaluation.Statistical considerations
Sample size and power calculations
The sample size was estimated initially to be 9,600, 
assuming an annual 3.8% primary composite cardiovas-
cular end point event rate, 1% annual lost to follow-up 
rate, 5% annual study drug discontinuation rate, and with 
a 60:40 ratio of those with or without a history of 
cardiovascular disease. Given that the observed (blinded) 
overall primary end point event rate to date was lower 
than expected, the sample size was increased to 14,000 in 
2013, and the proportion of patients with history of 
cardiovascular disease at entry increased to approximate-
ly 70%. The power to assess the primary safety objective 
of noninferiority of once-weekly exenatide compared 
with placebo will be N90%.
Analysis plan
Kaplan-Meier curves for time to the first occurrence of 
a primary composite end point event will be used to 
depict the accumulation of events over time for the 
once-weekly exenatide and placebo treatment groups. 
The hazard ratio comparing the time to first occurrence 
of the primary composite end point event for the 
once-weekly exenatide-treated group with that of the 
placebo-treated group and its 95% CI will be estimated 
using a Cox proportional hazards model stratified by 
baseline and cardiovascular risk group (prior cardiovas-
cular event or no prior cardiovascular event) and using 
treatment group as a covariate. Proportionality of the 
hazards over time by randomized treatment group will be 
tested.
The primary efficacy hypothesis of superiority will be 
assessed by a superiority analysis in the intent-to-treat 
(ITT) population. Superiority will be concluded if the 
upper limit of the 95% CI is b1.00. Appropriate alpha 
adjustment will be made for the 2 formal interim efficacy 
analyses that will be performed by the independent 
DSMB statistician. These are planned to occur after 
approximately one-third and two-thirds of the 1,360 
primary composite cardiovascular events required have 
been adjudicated.
The primary safety hypothesis will be assessed by a 
noninferiority analysis in the ITT population. Noninferi-
ority will be concluded if the upper limit of the 95% CI is 
b1.30, as per the 2008 FDA Guidance.26 Secondary and 
exploratory efficacy end points (Supplementary Appen-
dix B) will be analyzed individually in the ITT population. 
Prespecified subgroup analyses for the primary compos-
ite cardiovascular outcome are listed in Supplementary 
Appendix C.Biomarker and genetic assessments
Two optional substudies are included in EXSCEL for the
first 9,600 patients to be recruited. A genetic substudy
aims to collect whole blood samples at baseline for future
genetic research, and a biomarker substudy will collect
urine and blood samples before study drug exposure and
annually thereafter for proteomic and metabolomic
research. Separate consent will be obtained for each of
these substudies.Health economic analysis
EXSCEL will collect physician-reported data on re-
source use and patient-reported quality of life to
undertake cost-effectiveness analyses relevant to the
countries taking part in the study. Resource use data on
hospitalizations, visits, and medications will be combined
with appropriate national unit costs to calculate a cost
per patient per year. Quality of life data will be combined
with survival data to calculate quality-adjusted time in the
trial per patient.Study organization
EXSCEL is run jointly by 2 academic research organi-
zations, the Duke Clinical Research Institute (Durham,
NC) and the University of Oxford Diabetes Trials Unit
(Oxford, UK), in an academic collaboration with
pharmaceutical companies. Amylin Pharmaceuticals Inc
(San Diego, CA) was the original sponsor, later joined in
an alliance with Eli Lilly and Company (Indianapolis, IN).
Subsequently, sponsorship transitioned to Bristol-Myers
Squibb (Princeton, NJ) and AstraZeneca (Gaithersburg,
MD) with the acquisition of Amylin by Bristol-Myers
Squibb and has now transitioned to AstraZeneca alone,
with Amylin being a wholly owned subsidiary of
AstraZeneca.
Overall responsibility for the oversight and manage-
ment of the trial lies with the EXSCEL Executive
Committee, which is composed of 11 individuals,
comprising 9 senior independent academic representa-
tives who are experts in their field and 2 sponsor
representatives. A clinical events committee (CEC),
blinded to treatment allocation and consisting of physi-
cians including endocrinologists, cardiologists, and on-
cologists, will adjudicate all components of the primary
composite cardiovascular outcome, secondary end
points, and all cases of neoplasm and pancreatitis. The
EXSCEL DSMB, comprising independent statisticians and
specialists in diabetology, cardiovascular medicine, gas-
troenterology, and endocrine neoplasia, is responsible for
active surveillance of safety data including all cases of
neoplasm and pancreatitis. Members of the executive









The EXSCEL trial complies with the Declaration of
Helsinki, its subsequent revisions, and Good Clinical
Practice Guidelines. Institutional review board approval
has been obtained for all sites, and subjects sign informed
consent before any study procedures commence.





The EXSCEL trial will determine whether once-
weekly exenatide, on top of usual diabetes care,
reduces cardiovascular events in patients with T2DM
compared with usual diabetes care without a GLP-1
receptor agonist.
EXSCEL is the largest GLP-1 receptor agonist cardiovas-
cular outcome trial to date, recruiting 14,000 partici-
pants, and differs from other ongoing studies in a number 
of respects. Designed from the outset to test for 
superiority for the primary composite cardiovascular 
outcome, it will follow participants for up to 7 years with 
an expected median N3 years. EXSCEL will have around 
30% of patients with no history of prior cardiovascular 
disease to permit evaluation of possible primary, as well 
as secondary, cardiovascular risk reduction. By contrast, 
the ELIXA trial using lixisenatide (NCT01147250) in-
volves only patients with a recent history of acute 
coronary syndrome, whereas the REWIND trial using 
dulaglutide (NCT01394952) requires prior cardiovascular 
disease or the presence of at least 2 cardiovascular risk 
factors. Similarly, the SUSTAIN trial using semaglutide 
(NCT01720446) requires the presence of subclinical or 
overt cardiovascular disease. The LEADER trial using 
liraglutide (NCT01179048) uses a standardized recom-
mendation for the treatment of risk factors.
A patient-level integrated meta-analysis has showed no 
evidence for an increased cardiovascular disease risk 
associated with the use of exenatide twice-daily in 
subjects with T2DM,15 whereas a retrospective analysis 
of a medical and pharmaceutical insurance claims 
database found a lower relative cardiovascular disease 
risk associated with exenatide twice-daily treatment than 
with other glucose-lowering drugs.16 However, these 
database studies have several limitations including their 
retrospective nature, short duration, low baseline cardio-
vascular risk in the populations observed, and low 
cardiovascular disease event rates. These prior studies, 
while promising, are insufficient in establishing the 
cardiovascular safety and efficacy of exenatide once-
weekly in a population at increased risk of cardiovascular 
disease. Since EXSCEL was designed, 2 cardiovascular 
safety studies of dipeptidyl peptidase–4 (DPP-4) inhibi-
tors saxagliptin27 and alogliptin28 have reported nonin-
feriority to placebo with respect to their primary 
cardiovascular safety outcomes.There are several mechanisms whereby once-weekly
exenatide could potentially have a beneficial effect on
cardiovascular outcomes. It improves hyperglycemia and
other cardiovascular risk factors such as blood pressure,
lipids, and body weight without increasing the risk of
hypoglycemia.7-11 In addition, further pleiotropic effects
on the cardiovascular system, through both GLP-1
receptor–mediated and other mechanisms, have been
suggested.29 Studies in animal models suggest beneficial
effects of GLP-1 on atherogenesis by inhibiting the
inflammatory response in macrophages and endothelial
adhesion30 and modulating endothelial function.31,32
Further cardioprotective effects, by means of increased
coronary flow,29 reduced myocardial infarct size,33 and
improved left ventricular function, have also been
suggested by animal data.30,34 Human mechanistic
studies are consistent with these findings demonstrating
an improvement in flow-mediated vasodilation in the
postprandial state,13 reduced infarct size in patients with
ST-segment elevation myocardial infarction,12,14 and an
improvement in left ventricular ejection fraction in
patients with heart failure.35 These data together justify
the conduct of a large-scale, adequately powered
outcome trial testing for the superiority of a diabetes
treatment regimen containing once-weekly exenatide on
cardiovascular outcomes.Safety considerations
Studies with supratherapeutic GLP-1 receptor agonist
doses in rodents have shown an increase in thyroid C-cell
adenomas and carcinomas.24,33 In contrast to rodents,
GLP-1 receptor expression on primate thyroid C-cells is
very low, and no changes have been observed with in
vitro stimulation of human C-cells by GLP-1 receptor
agonists.10,24 Patients with a personal or family history of
medullary thyroid cancer or multiple endocrine neoplasia
type 2 will be excluded from ESXCEL. Patients random-
ized into EXSCEL will have their study medication
discontinued if their screening calcitonin value is N40
ng/L or subsequent annual values are ≥50 ng/L.
Concerns have been raised about the potential
association of incretin-based therapies with pancreatitis
and pancreatic cancer.36,37 Any putative cases of
pancreatitis or neoplasm of any type reported in EXSCEL
participants will be captured as clinical events of interest
and adjudicated. These data, along with observations
from other long-term studies, will contribute to clarifying
the risk-benefit analysis of these therapies.
As once-weekly exenatide is cleared by renal filtration
and subsequent tubule degradation,23 patients with an
eGFR b30 mL/(min 1.73 m2) will be excluded, and study
medication will be discontinued in those whose eGFR
falls below this value on 2 successive measurements.
The recently reported results of the SAVOR TIMI 53
trial showed an unexpected but statistically significant
27% increased relative risk for hospitalization for 
congestive heart failure with saxagliptin, a DPP-4 
inhibitor.26 Although the mechanism of action of DPP-4 
inhibitors differs from that of GLP-1 receptor agonists, 
hospitalization for congestive heart failure is a prespeci-
fied EXCSEL secondary outcome, with all putative events 
adjudicated by the CEC and reviewed regularly in an 
unblinded manner by the DSMB.
Challenges
More than a dozen concurrent cardiovascular outcome 
trials are currently ongoing, aiming to collectively enroll 
in excess of 100,000 patients with T2DM,38 creating a 
competitive environment for recruitment. In addition, 
the increasing availability of open-label once-weekly 
exenatide and other GLP-1 receptor agonists further 
constrains the number of eligible participants.
Retaining participants in EXSCEL and achieving high 
concordance with an injectable therapy create a chal-
lenge, especially as 50% of participants will receive 
placebo injections for a number of years. However, all 
patients who prematurely discontinue study treatment 
will be encouraged to continue subsequent study visits 
and posttreatment follow-up evaluations. 
Conclusion
In summary, EXSCEL is an ongoing multinational, 
double-blind, placebo-controlled, randomized trial of 
once-weekly exenatide that will provide important 
data on its long-term cardiovascular safety and
potential cardiovascular benefit. Given its pragmatic 
design, inclusion of patients with a broad range of 
cardiovascular risk, and no restrictions on concomitant 
glucose-lowering therapies (other than GLP-1 receptor 
agonists), the trial is expected to provide results that 
are generalizable and directly transferable to daily 
patient care.H.S. (none).
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